Literature DB >> 8018412

Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines.

A Nehme1, A M Julia, S Jozan, C Chevreau, R Bugat, P Canal.   

Abstract

Cytotoxic interactions between recombinant human interferon-gamma (IFN gamma) and cisplatin have been studied in six ovarian cell lines (IGROV1, NIHOVCAR3, SKOV3, OVCCR1, 2008 and its cisplatin resident variant 2008/C13*). Studies were performed using a cell survival assay. Results were assessed using median effect analysis. Synergy between these two drugs was observed in cell lines sensitive to IFN gamma, whatever their relative sensitivity or resistance to cisplatin, suggesting that IFN gamma enhances the cytotoxic activity of cisplatin. This interaction is not due to an increase in platinum accumulation in cells. This combination of drugs should be evaluated against human ovarian cancer xenografts in nude mice before its use in clinical practice.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018412     DOI: 10.1016/0959-8049(94)90430-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

Review 1.  The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.

Authors:  Lana E Kandalaft; Nathan Singh; John B Liao; Andrea Facciabene; Jonathan S Berek; Daniel J Powell; George Coukos
Journal:  Gynecol Oncol       Date:  2009-12-02       Impact factor: 5.482

2.  Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells.

Authors:  C Marth; M Widschwendter; J Kaern; N P Jørgensen; G Windbichler; A G Zeimet; C Tropé; G Daxenbichler
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial.

Authors:  G H Windbichler; H Hausmaninger; W Stummvoll; A H Graf; C Kainz; J Lahodny; U Denison; E Müller-Holzner; C Marth
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.